|
Sex, male (vs. female)
|
52/89
|
1.598 (0.834–3.064)
|
0.158
|
1.239 (0.724–2.118)
|
0.435
|
|
Age, ≥ 60 (vs. < 60)
|
23/89
|
1.330 (0.705–2.512)
|
0.379
|
1.714 (1.007–2.917)
|
0.047
|
|
Stage, III and IV (vs. I and II)
|
53/89
|
4.540 (1.986–10.375)
|
< 0.001
|
2.342 (1.303–4.208)
|
0.004
|
|
Tumor size, > 5 cm (vs. ≤ 5 cm)
|
54/89
|
1.582 (0.802–3.120)
|
0.186
|
1.157 (0.672–1.991)
|
0.600
|
|
LN metastasis, presence (vs. absence)
|
12/89
|
2.834 (1.340–5.994)
|
0.006
|
2.076 (1.043–4.134)
|
0.038
|
|
Distant metastasis, presence (vs. absence)
|
24/89
|
5.976 (3.152–11.331)
|
< 0.001
|
4.097 (2.351–7.139)
|
< 0.001
|
|
Histological grade, high (vs. low)
|
71/89
|
16.434 (2.237–120.748)
|
0.006
|
3.313 (1.411–7.777)
|
0.006
|
|
Tumor differentiation, 2 and 3 (vs. 1)
|
82/89
|
2.041 (0.491–8.481)
|
0.326
|
0.899 (0.357–2.260)
|
0.820
|
|
Mitotic count, ≥ 10/10 HPF (vs. 0–9/10 HPF)
|
53/89
|
3.548 (1.620–7.772)
|
0.002
|
2.196 (1.225–3.937)
|
0.008
|
|
Tumor necrosis, presence (vs. absence)
|
41/89
|
4.792 (2.331–9.853)
|
< 0.001
|
2.209 (1.294–3.771)
|
0.004
|
|
nIL4Rα, positive (vs. negative)
|
49/89
|
5.249 (2.398–11.493)
|
< 0.001
|
3.750 (2.051–6.855)
|
< 0.001
|
|
cIL4Rα, positive (vs. negative)
|
56/89
|
4.099 (1.799–9.339)
|
< 0.001
|
3.394 (1.782–6.464)
|
< 0.001
|
|
nIL13Rα1, positive (vs. negative)
|
45/89
|
9.451 (3.938–22.683)
|
< 0.001
|
6.546 (3.499–12.248)
|
< 0.001
|
|
cIL13Rα1, positive (vs. negative)
|
40/89
|
2.902 (1.510–5.579)
|
0.001
|
2.305 (1.353–3.924)
|
0.002
|
